Curcumin for COVID-19: real-time analysis of all 7 studies

Home

Database of all curcumin COVID-19 studies. Studies typically use advanced formulations for greatly improved bioavailability. Submit updates/corrections.


Jul 9	Early	Panda et al., Medicine, doi:10.1097/MD.0000000000026601 (Peer Reviewed)		The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
	Details Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability.
Jul 9	Details Source PDF Early treatment study Early treatment study
	Panda et al., Medicine, doi:10.1097/MD.0000000000026601 (Peer Reviewed)
	The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation
	Bioavailability RCT comparing CURCUGEN, a 50% curcuminoids-concentrated turmeric extract, with curcuminoids 95% standardized extract (C-95), showing significant improvements in bioavailability. Panda et al., 7/9/2021, peer-reviewed, 4 authors.
	Share Tweet Submit Corrections or Comments
Jun 29	In Vitro	Guijarro-Real et al., Foods, doi:10.3390/foods10071503 (Peer Reviewed) (In Vitro)	in vitro	Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
	Details In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLPro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLPro activity, but did not fully account for the inhibitory effect of turmeric rh..
Jun 29	Details Source PDF In Vitro In Vitro
	Guijarro-Real et al., Foods, doi:10.3390/foods10071503 (Peer Reviewed) (In Vitro)
	Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity
	In Vitro study of several plant extracts, showing strong inhibition of SARS-CoV-2 3CLPro activity by turmeric rhizomes. Commercial curcumin also inhibited 3CLPro activity, but did not fully account for the inhibitory effect of turmeric rhizomes extracts, suggesting that other components of the turmeric extract also play a main role in inhibiting 3CLPro activity. Guijarro-Real et al., 6/29/2021, peer-reviewed, 5 authors.
	Share Tweet Submit Corrections or Comments
Jun 19	Early	Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 (Peer Reviewed)	hosp., ↓85.7%, p=0.24	Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
	Details RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.
Jun 19	Details Source PDF Early treatment study Early treatment study
	Ahmadi et al., Food Science and Nutrition, doi:10.1002/fsn3.2226 (Peer Reviewed)
	Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial
	RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment. risk of hospitalization, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), continuity correction due to zero event. recovery time, 20.6% lower, relative time 0.79, p = 0.37, treatment 30, control 30. Ahmadi et al., 6/19/2021, Double Blind Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 11 authors.
	Share Tweet Submit Corrections or Comments
Jun 17	In Vitro	Goc et al., PLOS ONE, doi:10.1371/journal.pone.0253489 (Peer Reviewed) (In Vitro)	in vitro	Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions
	Details In Vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen fo..
Jun 17	Details Source PDF In Vitro In Vitro
	Goc et al., PLOS ONE, doi:10.1371/journal.pone.0253489 (Peer Reviewed) (In Vitro)
	Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions
	In Vitro study of 56 polyphenols showing that curcumin has high binding affinity to the RBD of the SARS-CoV-2 spike protein, inhibits ACE2 at non-toxic concentrations, and decreases activity of TMPRSS2. Promising results were also seen for brazilin and theaflavin-3,3’-digallate. Goc et al., 6/17/2021, peer-reviewed, 4 authors.
	Share Tweet Submit Corrections or Comments
May 28	Early	Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 (Peer Reviewed)	death, ↓81.8%, p=0.02	Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
	Details RCT 140 patients, 70 treated with curcumin and piperine (for absorption), showing faster recovery, lower progression, and lower mortality with treatment. Control group partients also received probiotics. CTRI/2020/05/025482.
May 28	Details Source PDF Early treatment study Early treatment study
	Pawar et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362 (Peer Reviewed)
	Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial
	RCT 140 patients, 70 treated with curcumin and piperine (for absorption), showing faster recovery, lower progression, and lower mortality with treatment. Control group partients also received probiotics. CTRI/2020/05/025482. risk of death, 81.8% lower, RR 0.18, p = 0.02, treatment 2 of 70 (2.9%), control 11 of 70 (15.7%). risk of death, 60.0% lower, RR 0.40, p = 0.39, treatment 2 of 15 (13.3%), control 5 of 15 (33.3%), severe group. risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), continuity correction due to zero event, moderate group. risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), continuity correction due to zero event, mild group. Pawar et al., 5/28/2021, Double Blind Randomized Controlled Trial, India, South Asia, peer-reviewed, 8 authors.
	Share Tweet Submit Corrections or Comments
May 7	Review	Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review) (Peer Reviewed)	review	Curcumin as a Potential Treatment for COVID-19
	Details Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects.
May 7	Details Source PDF Review Review
	Rattis et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287 (Review) (Peer Reviewed)
	Curcumin as a Potential Treatment for COVID-19
	Review of curcumin for COVID-19 including potential antiviral, anti-inflammatory, anticoagulant, antiplatelet, and cytoprotective effects. Rattis et al., 5/7/2021, peer-reviewed, 3 authors.
	Share Tweet Submit Corrections or Comments
Jan 3	Early	Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 (Peer Reviewed)	progression, ↓94.3%, p=0.001	Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
	Details Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.
Jan 3	Details Source PDF Early treatment study Early treatment study
	Saber-Moghaddam et al., Phytotherapy Research, doi:10.1002/ptr.7004 (Peer Reviewed)
	Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial
	Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1. risk of disease progression, 94.3% lower, RR 0.06, p = 0.001, treatment 0 of 21 (0.0%), control 8 of 20 (40.0%), continuity correction due to zero event. risk of no recovery, 38.4% lower, RR 0.62, p = 0.04, treatment 11 of 21 (52.4%), control 17 of 20 (85.0%). hospitalization time, 44.8% lower, relative time 0.55, p < 0.001, treatment 21, control 20. Saber-Moghaddam et al., 1/3/2021, prospective, Iran, Middle East, peer-reviewed, 9 authors.
	Share Tweet Submit Corrections or Comments
Oct 20 2020	Late	Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 (Peer Reviewed)	death, ↓50.0%, p=0.30	Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
	Details Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mR..
Oct 20 2020	Details Source PDF Late treatment study Late treatment study
	Valizadeh et al., Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088 (Peer Reviewed)
	Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients
	Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may improve clinical outcomes. risk of death, 50.0% lower, RR 0.50, p = 0.30, treatment 4 of 20 (20.0%), control 8 of 20 (40.0%). Valizadeh et al., 10/20/2020, Double Blind Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 12 authors.
	Share Tweet Submit Corrections or Comments

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit